Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar.
Premedical Division, Weill Cornell Medicine-Qatar, Doha, Qatar.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2212568. doi: 10.1080/21645515.2023.2212568.
The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.
2021 年 10 月检测到了 SARS-CoV-2 的奥密克戎变体，与早期变体相比，它具有更高的传染性、免疫逃逸能力和更低的严重程度。奥密克戎对疫苗的效力较低，其严重程度降低，这在公众中造成了对疫苗接种的犹豫。本综述汇编了报告奥密克戎与早期变体相对流行率的数据，以深入了解可能影响新开发疫苗目标的现有变体。综合数据显示，在一些国家的感染人群中，奥密克戎的流行率超过 90%。在奥密克戎浪潮的早期阶段，BA.1 亚变体比 BA.2 更为流行。此外，2021 年 10 月至 2022 年 4 月期间，南非、美国和意大利也检测到了 BA.4/BA.5 亚变体。因此，开发既能预防奥密克戎又能预防早期变体的疫苗非常重要，因为早期变体已知会导致更严重的并发症。
